Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bloodwise and NCRI Working Group Pick a Winner Programme (LI-1)
2011-000749-19Phase 2Unknown
- Sponsor
- Cardiff University
- Start
- Apr 2011
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quizartinib, tosedostat, selinexor, lenalidomide, arginase-1 and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Cardiff University. Primary endpoints: Complete remission rate, Relapse and 1 more. Status: unknown.
02
Drugs
quizartinibtosedostatselinexorlenalidomidearginase-1
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2011-000749-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000749-19.